These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6360031)

  • 21. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of galantamine treatment on caregiver time in Alzheimer's disease.
    Sano M; Wilcock GK; van Baelen B; Kavanagh S
    Int J Geriatr Psychiatry; 2003 Oct; 18(10):942-50. PubMed ID: 14533127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D; Andersen HF
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease.
    Prescrire Int; 2003 Dec; 12(68):203-5. PubMed ID: 14986682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of long-term physostigmine administration in Alzheimer's disease.
    Harrell LE; Callaway R; Morere D; Falgout J
    Neurology; 1990 Sep; 40(9):1350-4. PubMed ID: 2392216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.
    Davis KL; Mohs RC
    Am J Psychiatry; 1982 Nov; 139(11):1421-4. PubMed ID: 6753611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypertension associated with oral administration of physostigmine in a patient with Alzheimer's disease.
    Cain JW
    Am J Psychiatry; 1986 Jul; 143(7):910-2. PubMed ID: 3717434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease.
    Thal LJ; Masur DM; Blau AD; Fuld PA; Klauber MR
    J Am Geriatr Soc; 1989 Jan; 37(1):42-8. PubMed ID: 2642499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial.
    Jenike MA; Albert M; Baer L; Gunther J
    J Geriatr Psychiatry Neurol; 1990; 3(1):13-6. PubMed ID: 2189429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physostigmine in patients with Alzheimer's disease.
    Davidson M; Mohs RC; Hollander E; Davis BM; Ryan T; Horvath TB; Davis KL
    Psychopharmacol Bull; 1986; 22(1):101-5. PubMed ID: 3726054
    [No Abstract]   [Full Text] [Related]  

  • 31. Action of physostigmine on inherited ataxias.
    Rodriguez-Budelli MM; Kark RA; Blass JP; Spence MA
    Adv Neurol; 1978; 21():195-202. PubMed ID: 735925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physostigmine effects in Alzheimer's disease: relationship to dementia severity.
    Schwartz AS; Kohlstaedt EV
    Life Sci; 1986 Mar; 38(11):1021-8. PubMed ID: 3512944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies.
    Mohs RC; Davis BM; Greenwald BS; Mathé AA; Johns CA; Horvath TB; Davis KL
    J Am Geriatr Soc; 1985 Nov; 33(11):749-57. PubMed ID: 2865282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Etiology, clinical aspects and therapy of Alzheimer's disease].
    Aschoff J
    Krankenpfl J; 1990; 28(1-2):14-8. PubMed ID: 2314041
    [No Abstract]   [Full Text] [Related]  

  • 35. A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease.
    Bierer LM; Aisen PS; Davidson M; Ryan TM; Stern RG; Schmeidler J; Davis KL
    Alzheimer Dis Assoc Disord; 1993; 7(2):98-104. PubMed ID: 8347333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease.
    Sano M; Bell K; Marder K; Stricks L; Stern Y; Mayeux R
    Clin Neuropharmacol; 1993 Feb; 16(1):61-9. PubMed ID: 8422658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl.
    Sunderland T; Molchan S; Lawlor B; Martinez R; Mellow A; Martinson H; Putnam K; Lalonde F
    Int Psychogeriatr; 1992; 4 Suppl 2():291-309. PubMed ID: 1288668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG.
    Gustafson L; Edvinsson L; Dahlgren N; Hagberg B; Risberg J; Rosén I; Fernö H
    Psychopharmacology (Berl); 1987; 93(1):31-5. PubMed ID: 3114812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level.
    Beller SA; Overall JE; Swann AC
    Psychopharmacology (Berl); 1985; 87(2):147-51. PubMed ID: 3931138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease.
    Harrell LE; Jope RS; Falgout J; Callaway R; Avery C; Spiers M; Leli D; Morere D; Halsey JH
    J Am Geriatr Soc; 1990 Feb; 38(2):113-22. PubMed ID: 2405043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.